3-[(4-ethylphenyl)methyl]-1-[(3R,4S,5R,6R)-3,4,5-tributoxy-6-(butoxymethyl)oxan-2-yl]indole

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: 3-[(4-ethylphenyl)methyl]-1-[(3R,4S,5R,6R)-3,4,5-tributoxy-6-(butoxymethyl)oxan-2-yl]indole
• 化学式: C₃₉H₅₉NO₅
• 分子量: 621.9
• InChiKey: WJSLEFKDLSURNU-WVTZLKINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  45
• 可旋转键数：
  21
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• GLUCOPYRANOSIDE COMPOUND
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20140296506A1

  公开（公告）日：2014-10-02

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物的公式如下：其中环A和环B为：（1）环A是可选取代的不饱和单环杂环，环B是可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A是可选取代的苯环，环B是可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或（3）环A是可选取代的不饱和融合杂双环，环B是独立的可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X为碳原子或氮原子；Y为—（CH2）n—（n为1或2）；或其药学上可接受的盐或前药。
• Novel compounds having inhibitory activity against sodium-dependant glucose transporter
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2896397A1

  公开（公告）日：2015-07-22

  Use of a compound of formula (IA): wherein RA is a halogen atom, a lower alkyl group or a lower alkoxy group; RB is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; and Rc is hydrogen atom; or RB and RC taken together are a fused benzene ring which may be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; in combination with another antidiabetic agent, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent, in the manufacture of a medicament for the treatment of diabetes mellitus (type 1 and type 2), diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, postprandial hyperglycemia, or delayed wound healing.

  使用式(IA)化合物： 其中 RA 是卤素原子、低级烷基或低级烷氧基；RB 是任选被卤素原子、氰基、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基或单或双低级烷基氨基取代的苯基；或可被卤素原子、氰基、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基或单低或双低烷基氨基取代的杂环基团；且 Rc 为氢原子；或 RB 和 RC 合在一起为可被卤素原子、低级烷基、卤代低级烷基、低级烷氧基或卤代低级烷氧基取代的融合苯环； 与另一种抗糖尿病药、抗肥胖药、抗高血压药、抗血小板药、抗动脉粥样硬化药和/或降血脂药联用、 用于制造治疗糖尿病（1 型和 2 型）、糖尿病视网膜病变、糖尿病神经病变、糖尿病肾病、餐后高血糖或伤口延迟愈合的药物。
• NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3251679A1

  公开（公告）日：2017-12-06

  Use of a compound of formula (IA): wherein RA is a halogen atom, a lower alkyl group or a lower alkoxy group; RB is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; and Rc is hydrogen atom; or RB and RC taken together are a fused benzene ring which may be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; in the manufacture of a medicament for the treatment of diabetes mellitus (type 1 and type 2), diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, postprandial hyperglycemia, or delayed wound healing.

  使用式(IA)化合物： 其中 RA 是卤素原子、低级烷基或低级烷氧基；RB 是任选被卤素原子、氰基、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基或单或双低级烷基氨基取代的苯基；或可被卤素原子、氰基、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基或单低或双低烷基氨基取代的杂环基团；且 Rc 为氢原子；或 RB 和 RC 合在一起为可被卤素原子、低级烷基、卤代低级烷基、低级烷氧基或卤代低级烷氧基取代的融合苯环； 用于制造治疗糖尿病（1 型和 2 型）、糖尿病视网膜病变、糖尿病神经病 变、糖尿病肾病、餐后高血糖或伤口延迟愈合的药物。
• US8785403B2
  申请人：——

  公开号：US8785403B2

  公开（公告）日：2014-07-22